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The combination of irinotecan (CPT-11), oxaliplatin (L-OHP), 5-fluorouracil (5-FU) and folinic acid (FA) is one of the possibilities to
overcome chemoresistance in advanced colorectal cancer (ACRC) patients. The aim of this study was to determine the tolerability
and activity of CPT-11 plus chronomodulated infusion of L-OHP, 5-FU and FA in ACRC patients. A total of 35 patients (91%
pretreated, 77% with CPT-11, 54% with L-OHP, 42% with both) were treated every 3 weeks with CPT-11, 180mgm
 2 day 1 i.v.,
plus L-OHP, 20mgm
 2day
 1, 5-FU, 700mgm
 2day
 1 and FA, 150mgm
 2day
 1, all three drugs from day 2 to day 5 by
chronomodulated infusion. The patients’ (pt) data were as follows: male/female 21/14; median age 58years (range: 38–70); PS 0: 26
pts (74%), PS 1: 8 pts (23%), PS 2: 1 pt (3%); primary tumour colon/rectum 26/9; involved organs: 1, 14 pts (40%); 2, 17 pts (48%);
X3: 4 pts (11%); previous chemotherapy lines 1: 12 pts (34%), 2: 10 pts (28%), X3: 10 pts (28%). A total of 221 courses (c) were
performed; no grade 4 toxicity was observed with only one grade 3 (G3) neutropenia and thrombocytopenia (3%) in one out of 221
courses (o1%). Maximal toxicity (G3) was nausea and diarrhoea in 10 pts (28%), occurring in 14 out of 221 c (6%) and 12 out of
221 c (5%) respectively. Seven patients achieved a partial response (20%, confidence interval (c.i.) 6.8–33.3) and one patient a
complete response (2.9%, c.i. 0–8.4), for a total overall response rate of 22.9% (c.i. 9–36.8); 15 out of 35 (42.9%, c.i. 26.5–59.3) had
stable disease and 12 out of 35 (34.3%, c.i. 18.6–50) patients underwent a progression. In conclusion, this four-drug regimen is
feasible in advanced pretreated ACRC patients with no significant haematological toxicity and acceptable diarrhoea. The activity of
this combination is currently studied in EORTC 05011 study.
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During the last decade, the introduction of new drugs such as
irinotecan (CPT-11) and oxaliplatin (L-OHP) modified the
management of metastatic colorectal cancer (CRC). Both drugs
had shown activity as a single agent and in combination with 5-
fluorouracil (5-FU), with a different mechanism of action and
without cross-resistance: SN 38, the active metabolite of CPT-11,
inhibits DNA topoisomerase I. L-OHP induces the formation of
DNA adducts, inhibiting DNA synthesis.
In the last few years, prospective randomised phase III trials
comparing both continuous infusion and bolus 5-FU plus folinic
acid (FA) vs the same schedule plus CPT-11 or L-OHP showed
significant increase of response rate (RR), time to progression
(TTP), overall survival (OS), no quality of life (QoL) detriment
with acceptable toxicity profile (De Gramont et al, 2000; Douillard
et al, 2000; Saltz et al, 2000; Goldberg et al, 2002).
These results suggest that combination of infusional 5-FU plus
L-OHP or CPT-11 can now be considered as the standard treatment
in this setting of patients.
Drug delivery according to circadian rhythm showed an impact
on toxicity profile and activity both in preclinical and in clinical
setting (Le ´vi, 2001). It was demonstrated in phase III trials that
the combination of L-OHP plus 5-FU and FA delivered by
chronomodulated infusion, the FFL regimen, provides more
activity and a better toxicity profile when compared to the flat
infusion of the same drugs with a five-fold greater mucositis rate
due to 5-FU and the double of peripheral neurotoxicity due to L-
OHP in the constant infusion regimen (Le ´vi et al, 1994, 1997).
Circadian changes in drug pharmacokinetics, target tissue
susceptibility, bone marrow DNA synthesis, 5-FU metabolic and
catabolic enzymatic activity (thymidylate phosphorylase and
dehydropyrimidine dehydrogenase) and oral/rectal epithelium
during night hours vs light hours are some of the explanations
of these differences. Concerning drug activity 5-FU dose-intensity
seems to be related to drug activity and this could influence
survival (Le ´vi et al, 1999; Garufi et al, 1997).
The combination of CPT-11 and L-OHP without 5-FU was also
investigated in phase I and II studies, which showed the activity of
these drugs in patients heavily pretreated with 5-FU-based regimen
(Scheiteuer et al, 1999; Wassermann et al, 1999). Haematologic
toxicity has been commonly observed; grade 3–4 (G3–4)
neutropenia occurred in 20–33% of patients even though
concomitant granulocyte colony-stimulating factor (G-CSF) ad-
ministration. Synergistic in vitro experimental evidence of activity
between these two drugs were found: pre-exposure to L-OHP
enhances the cytotoxic effects of SN38 by increasing topoisomerase
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lI activity by a stabilisation of DNA platinum adducts, the duration
and extent of DNA and RNA synthesis inhibition and through a
prolonged DNA elongation inhibition (Zeghari-Squalli et al, 1999).
In vitro model on CRC cell lines had suggested that the activity of
SN-38 is synergic to L-OHP plus 5-FU-FA when delivered 24–48h
before.
The preclinical data cited above strongly support the attempt to
overcome the chemoresistant clones using all active drugs together
with an acceptable cost in terms of patient tolerability. Now, we
present the results of a phase II trial designed to determine the
toxicity profile and activity of the combination of CPT-11 plus
L-OHP, 5-FU and FA by chronomodulated infusion in heavily
pretreated metastatic CRC patients.
MATERIALS AND METHODS
Patient eligibility
Histologically proven locally advanced or metastatic colorectal
cancer; age at least 18 years old; Performance status (World Health
Organization) 0–2; measurable disease; life expectancy of at least 3
months; adequate haematologic parameters (white blood cells,
WBC X3.5 10
9l
 1, absolute neutrophil count X1.5 10
9l
 1,
platelets X100 10
9l
 1, haemoglobin X10gdl
 1); bilirubin
p1.25 upper normal limit (UNL); alanine aminotransferase
(ALT) and aspartate aminotransferase (AST) p2.5 UNL; or
bilirubin p1.5 UNL, ALT and AST p5 UNL in patients with
liver metastases; serum albumin X3gl
 1; and normal renal
function, with serum creatinine p1.25 UNL and creatinine
clearance of at least 60mlmin
 1; previous chemotherapy for
metastatic disease was allowed. Patients were considered not
eligible for the following reasons: secondary primary tumour other
than nonmelanoma skin cancer or in situ cervical carcinoma;
metastatic lesion suitable for surgical resection of elective radio-
therapy; inflammatory bowel diseases or chronic diarrhoea that
requires treatment; total colectomy or ileostomy; bowel obstruc-
tion and/or subobstruction; severe diarrhoea (WHO G3–4) during
prior 5-FU or CPT-11 chemotherapy; uncontrolled metabolic
disorders or active infections; uncontrolled cardiac arrhythmias;
uncontrolled congestive heart failure or severe ischaemic heart
disease; acute myocardial infarction in the last 6 months; history of
significant neurologic or psychiatric disorders; pregnancy or
breastfeeding; symptomatic brain metastases; prior irradiation
affecting more than 30% of active bone marrow; ongoing treatment
with other antiblastic agents or radiotherapy; functional grade 3
(G3) neuropathy due to L-OHP.
Pretreatment evaluation
Each patient had to sign written informed consent to enter the
study. Every patient was required to have a totally implanted,
double-lumen, central venous access port. Within 4 weeks before
starting the treatment, patients were required to perform baseline
imaging work-up by thorax, abdomen and pelvis CT scan; initial
blood sample not far than 1 week prior to start chemotherapy.
Patients had to be completely out of toxic effect of previous
treatment.
Chemotherapy
The schedule we applied in this study is based on the following: (a)
L-OHP 20mgm
2day
 1 plus 5-FU 600mgm
2day
 1 and FA
150mgm
2day
 1 by chronomodulated infusion were the starting
doses in the 3-weekly FFL schedule used in our phase III trials
(Le ´vi et al, 1994, 1997); (b) we previously conducted a phase II
study where CPT-11, 180mgm
 2 on day 1 in 1h by a 6-h
chronomodulated infusion, was combined to chronomodulated 5-
FU and FA from day 2 to day 5 (Garufi et al, 2002). To increase the
activity of this last combination, L-OHP at the dose of
20mgm
2die
 1 (days 2–5), was added to the previous CPT-11
(day 1) plus the 4-day (days 2–5) 5-FUFA chronomodulated
infusion every 3 weeks.
CPT-11 was administered during the morning as a 60min
intravenous (i.v.) infusion, dissolved in 250ml of 0.9% NaCl
solution, on day 1 at the dose of 180mgm
 2. Atropine was given
before CPT-11 to avoid cholinergic syndrome and loperamide was
suggested for delayed diarrhoea. L-OHP, 5-FU and FA were
administered by chronomodulated infusion using a multichannel,
programmable, in-time, ambulatory pump, equipped with four
channels (Melodie
s pump). Pumps were programmed using
Aguettant software. L-OHP infusion was administered from 1000
to 2200 with a diurnal peak at 1600 for 4 consecutive days (days
2–5) at the dose of 20mgm
 2day
 1 (days 2–5). 5-FU and FA
infusions were both delivered the same days from 2200 to
1000 with a nocturnal peak at 0400 at the dose of 700mgm
 2
day
 1 (5-FU) and FA was administered at the fixed dose
of 150mgm
 2day
 1 (Figure 1). Antiemetic prophylaxis with
anti-HT-3 was administered to each patient. No steroid medication
was allowed. Toxicity was evaluated after each course during
treatment according to WHO criteria. Treatment was planned
every 3 weeks, depending on patient compliance and tolerance to
treatment.
Dose modifications
Diarrhoea: CPT-11 dose was reduced to 130mgm
 2 and 5-FU dose
by 100mgm
 2day
 1 in the presence of G3–4 diarrhoea. Mucositis:
5-FU was reduced by 100mgm
 2day
 1 in the presence of G3–4
mucositis or cutaneous toxicity. Neutropenia: In case of absolute
neutrophil count p1.5 10
9l
 1 and/or platelet count p100 10
9l
 1,
treatment had to be delayed for 2 weeks maximum. No G-CSF
administration was allowed unless necessary. Neuropathy: L-OHP was
reduced to 15mgm
 2day
 1 in case of persistent (o14 days)
paresthesia or occurrence of functional impairment; X14 days
provided L-OHP discontinuation.
Patient evaluation
Tumour response were assessed using World Health Organization
criteria as follows: complete response (CR) was considered the
complete disappearance of all clinical palpable, endoscopical and
imaging evidence of tumour, determined by two observations not
less than 28 days apart. Partial response (PR) was defined as a
reduction greater or at least equal to 50% of the sum of the
products of the two longest diameters measured lesions. No
Time (clock hours)
Oxaliplatin (l-OHP): 20 mg m−2 day−1
5-FU  : 700 mg m−2 day−1
FA : 150 mg m−2 day−1
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Figure 1 Treatment schedule (for 5 days every 3 weeks).
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lincrease in the size of any lesion or appearance of new lesions must
have occurred. Stable disease (SD) was defined as a reduction less
than a PR, but without evidence of disease progression. Progres-
sion of disease (PD) was defined as an increase of at least 25% in
the product of measured lesion and/or appearance of new lesion
while the patient was on study. CT scanning was repeated every 4
weeks in case of CR or PR to confirm the response. The TTP was
defined as the interval between the first treatment and the first
documentation of disease progression. Time to treatment failure
(TTF) was defined as the interval between the first and the last day
of treatment. Duration of response was considered as the time
between first appearance of response and tumour progression.
Overall survival was measured from the time of starting treatment
to death or last contact with the patient.
RESULTS
Patient characteristics
From September 1999 to May 2002, 35 patients affected by
metastatic colorectal cancer entered the study. Patients’ character-
istics are listed in Table 1. The median age was 58 years (range 38–
70), 26 patients (74%) had WHO performance status of 0, 26
patients (74%) had colon as primary sites of disease and the liver
was the site of distant metastases in 26 patients (74%). In all, 11
patients (31%) had metachronous metastases and 24 (69%) had
synchronous distant metastasis. Out of 35 patients, 32 (91%) had
received first-line chemotherapy: all of these patients were
pretreated with 5-FU-based chemotherapy; 27 patients (77%) with
CPT-11 (median dose received 858mgm
 2), 19 patients (54%)
with L-OHP (median dose received 230mgm
 2), 15 patients (42%)
had previously received both CPT-11 and L-OHP.
Treatment toxicity
A total of 221 courses were administered, with a median number of
five courses (range 2–15). Median CPT-11 dose-intensity was
48.5mgm
2week
 1 (80.8% of the theoretical dose of 60mg
m
2week
 1); median L-OHP dose-intensity was 24.4mgm
2week
 1
(89.9% of the theoretical dose of 26.7mgm
2week
 1); median 5-FU
dose-intensity was 840mgm
2week
 1 (90% of the theoretical dose
of 933.3mgm
2week
 1). All patients were assessable for toxicity.
The overall toxicity per patient and per course are shown in
Table 2, respectively. Neither febrile neutropenia was registered
nor any other grade 4 (G4) toxicity occurred. The most serious G3
toxicities were nausea and diarrhoea, which occurred in 10 of 35
patients (28.5%). G3 vomiting was present in eight patients (23%).
The most frequent G3 toxicities was nausea, occurred in 13 out of
221 courses (6%), diarrhoea, 1 out of 221 (5%) and vomiting, eight
out of 221 (3.5%). Four of 35 patients (11.5%) had G3 asthenia,
which occurred in six out of 221 courses (2.5%).
Treatment efficacy
All patients were evaluable for response. Seven patients achieved
PR (20%, confidence interval c.i. 6.8–33.3) and one patient CR
(2.9%, c.i. 0–8.4), for a total overall response rate (ORR) of 22.9%
(c.i. 9–36.8); 15 patients (42.9%, c.i. 26.5–59.3) had SD. A total of
12 patients (34.3%, c.i. 18.6–50) deemed in progression (Table 3).
The median time of response duration was 4.5 months.
Efficacy and previous treatment
All the four CPT-11 and L-OHP untreated patients obtained an
objective response (one CR and three PR). One out of the four
L-OHP (25%) pretreated patients achieved a PR and three had SD.
A total of 12 patients had previously received only CPT-11 without
L-OHP: three of them (25%) had PR, four had SD, and four patients
underwent progressive disease. None of the 15 patients previously
treated with both CPT-11 and L-OHP achieved tumour reduction;
eight of them had SD and seven had progression of disease. Among
the six patient responders at the previous chemotherapy line, three
of them had PR (50%), one had no change of disease and two had
progression. A total of 13 patients had no change of disease at the
previous chemotherapy: nine of them maintain SD, one had PR
and three deemed in progression. Out of the 10 progressive
patients at the previous chemotherapy line, five achieved no
change of disease and five kept progressing. The median TTF was
3.5 months (c.i. 3–5). The median TTP and OS were 4.1 months
(c.i. 4–7) and 15.1 months (c.i. 10–18) respectively, with a median
follow-up of 8.5 months.
Table 1 Patient characteristics
No. of patients (total: 35) %
Age (years)
Median (range) 58 (38–70)
Gender
Male 21 60
Female 14 40
Performance status (WHO)
02 6 7 4
18 2 3
21 3
Primary tumour
Colon 26 74
Rectum 9 26
Site of metastasis
Liver 26 74
Lung 18 51
Lymph nodes 6 17
Peritoneum 5 14
Other 4 11
No. of organs involved
11 4 4 0
21 7 4 8
X34 1 1
Radiotherapy
Adjuvant 4 11
Palliative 6 17
No. of previous chemotherapy lines
11 2 3 4
21 0 2 8
X31 0 2 8
5-Fluorouracil-based chemotherapy
Adjuvant 12 34
Palliative 32 91
Previous chemotherapy
L-OHP 19 54
CPT-11 27 77
L-OHP+CPT-11 15 42
Baseline CEA
Median (range) 35.5 (1–7586)
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Four patients underwent surgery after chemotherapy. Two patients
who achieved PR after seven courses of treatment underwent lung
and liver metastasectomy, respectively; the patients with hepatic
resection received radical surgery and received further four
courses of the treatment. Two patients with SD underwent surgery
after chemotherapy; a patient received radical lung metasta-
sectomy and the other underwent cerebellar resection for brain
metastasis 3 months after progression of disease. Another patients
who obtained SD underwent liver termoablation of metastases; the
patient deemed in progression after further 3 months. The
majority of the patients who were considered suitable for further
chemotherapy received a combination containing mitomycin-C
plus UFT or 5-FU continuous infusion.
DISCUSSION
The treatment of advanced colorectal cancer changed profoundly
during the last 10 years. The best results in terms of RR, time to
progression and OS were obtained when infusional 5-FU and
leucovorin were combined to mitomycin-C, oxaliplatin or CPT-11.
At this moment, there is no standard rule regarding the optimal
dose and schedule of both 5-FU and oxaliplatin, while the use of
CPT-11 seems to be preferred in combination with FA and
infusional 5-FU (Douillard et al, 2000).
The chronomodulation of 5-FUFA plus L-OHP (FFL), developed
by Le ´vi and tested in several phase II and III trials, contributed to
the definition of a new strategy in this disease, including the
reduction of 5-FU and L-OHP toxic effects and the possibility to
use chemotherapy as a neoadjuvant therapy for advanced patients
in order to increase the number of patients suitable for surgery
after chemotherapy (Adam et al, 2000). So the next step was to
improve these results: the logical consequence was to add CPT-11
to the chronomodulated schedule of FFL.
From our point of view, the addition of CPT-11 to our standard
treatment, which is the chronomodulated regimen of FFL, is
justified if a synergistic rather than an additive effect can be
produced in order to avoid severe toxic effects in the majority of
patients. In this context, our group previously demonstrated in an
experimental mouse model that the synergy between CPT-11 and
L-OHP is obtained only when the two drugs are given at their
optimal timing, which is during the second half of activity span for
L-OHP and during the second half of rest span for CPT-11, coming
to a peak time of 1600 for L-OHP and of 0500 for CPT-11 in human
beings (Granda et al, 2002). At this time, there is no clear evidence
that CPT-11 chronomodulation can help to significantly increase
effectiveness or tolerability of this drug, when it is used alone or in
combination with 5-FU and it is compared to the standard 1-h
infusion regardless of peak timing (Garufi et al, 2002; Giachetti
et al, 2001).
Table 2 WHO toxicity criteria in 35 patients and 221 courses
Grade
12 3 4
Patients/courses % Patients/courses % Patients/courses % Patients/courses %
Haematologic toxicity
Anaemia 3/13 8.5/6 3/3 8.5/1 — — — —
Leucopenia 12/28 34/12.5 4/7 11.5/3 1/— 3/— — —
Neutropenia 10/26 28.5/11.5 4/7 11.5/3 1/1 3/0.5 — —
Thrombocytopenia —/1 —/0.5 1/1 3/1 1/1 3/0.5 — —
Nonhaematologic toxicity
Nausea 7/55 20/25 19/78 54/35 10/13 28.5/6 — —
Vomiting 9/63 25.5/28,5 14/31 40/14 8/8 23/3.5 — —
Diarrhoea 10/53 28.5/24 11/29 31.5/13 10/11 28.5/5 — —
Mucositis 6/17 17/7.5 6/10 17/4.5 3/3 8.5/1 — —
Cutaneous 5/14 14/6 — — — — — —
Neurotoxicity 7/60 20/27 2/6 6/2.5 — — — —
Asthenia 6/66 17/29.5 22/41 63/18.5 4/6 11.5/2.5 — —
Table 3 Overall response rate (ORR)
ORR (n/%) CR (n/%) PR (n/%) SD (n/%) PD (n/%)
All evaluable patients (n¼35) 8/22.9% 1/2.9% 7/20% 15/42.9% 12/34.3%
(intention to treat analysis) (c.i. 9–36.8) (c.i. 0–8.4) (c.i. 6.8–33.3) (c.i. 26.5–59.3) (c.i. 18.6–50)
Patients not pretreated with CPT-11 or L-OHP (n¼4) 1 1 3 — —
Patients pretreated with CPT-11 (n¼12) 3 — 3 4 5
Patients pretreated with L-OHP (n¼4) 1 — 1 3 —
Patients pretreated with both CPT-11 plus L-OHP (n¼15) — — — 8 7
CR¼complete response; PR¼partial response; SD¼stable disease; PD¼progression of disease; CPT-11¼irinotecan; L-OHP¼oxaliplatin.
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regimen, we tested 35 pretreated colorectal cancer patients. Our
results pointed out two points: the schedule we proposed is feasible
with an acceptable toxicity, mainly diarrhoea and nausea. It is
crucial to observe that we did not use steroids for nausea and
vomiting prevention because of their negative effects on circadian
coordination. The second point is that there is no activity
in patients previously treated separately with both CPT-11 and
L-OHP and 5-FU, and so the use of this four-drug combination in
this set of patients seems not to be justified as already found
when patients become resistant to combination of oxaliplatin
and infusional 5-FUFA (Andre ` et al, 1999; Tournigaud
et al, 2001).
Souglakos (Souglakos et al, 2002) and Falcone (Falcone
et al, 2002) recently published the first two trials with the
four-drug regimen with two different schedules in untreated
patients. There are some peculiar differences in patient
characteristics, tolerability and tumour response between
those trials and this one. Both of these authors treated naı ¨ve
patients so the response rate was 58.1 and 69%, respectively
but their schedules, given every 2 weeks, produced substantially
toxicity. Souglakos reported 32% of patients with diarrhoea but
45% of them displayed severe G3–4 neutropenia with 6% of
febrile neutropenia. Falcone also declared 14% of patients
with febrile neutropenia, 55% of them experiencing at least
one episode of G4 neutropenia and 21% G3 diarrhoea. In this
last trial, a semi-intermittent circadian delivery of 5-FU was
employed. Our major toxic effect was G3 diarrhoea and
nausea in 28.5% of patients but only 5 and 6% of 221 courses,
respectively.
Following the present experience and the reported experimental
data, the EORTC Chronotherapy Group is actually conducting a
trial in advanced colorectal cancer patients with the four-drug
combination where patients are randomised to six different peak
timings of CPT-11 on day 1 and receive chronomodulated FFL
from day 2 to day 5 every 3 weeks (EORTC 05011). This trial will
produce definitive clarification not only on the CPT-11 chron-
omodulation but also on the activity of this combination in naı ¨ve
patients.
In conclusion, the present paper showed that the addition of
CPT-11 to chronomodulated FFL is feasible with acceptable
toxicity in heavily pretreated patients. The activity of this schedule
and the role of CPT-11 chronomodulation is actually tested in
EORTC 05011 trial in naı ¨ve patients.
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